A pioneering rapid brain tumour test is dramatically transforming patient diagnosis across England. This innovative technology slashes the time for an accurate brain tumour diagnosis from weeks to mere hours. As a result, patients can begin vital treatments like radiotherapy and chemotherapy much sooner. Furthermore, they are spared lengthy periods of agonizing uncertainty.
Steve Palmer, a 55-year-old from Nottingham, directly benefited from this new approach. Surgeons received his diagnosis even while operating to remove his tumour. “Getting that quick diagnosis removed weeks of anxiety,” Palmer stated, expressing his relief. Palmer had collapsed at the gym, leading to his brain tumour discovery. The rapid test quickly identified it as a grade 4 glioblastoma. “It wasn’t the result I wanted to hear,” he admitted, “but it means I can get on with treatment and fighting this illness.”
The genomic test works by swiftly analysing the genetic code of a tumour sample. Small tissue samples are sent to a pathology lab. They are then prepared for a shoebox-sized sequencing machine, developed by Oxford Nanopore in collaboration with Nottingham University. This device uses specialist software to reveal the tumour’s unique genomic fingerprint. For example, in Steve’s case, the machine ran for just 20 minutes before a probable glioblastoma diagnosis was relayed to the operating theatre.
Consultant neurosurgeon Stuart Smith, who led Steve’s operation, described the test as “almost magical.” Traditional diagnosis often takes six to eight weeks for full molecular and genetic information. Now, this crucial data becomes available during surgery. This speed fundamentally alters surgical strategy. For instance, in curable tumour types, surgeons can perform more radical removals, aiming for every last bit. Conversely, with aggressive tumours beyond surgical cure, a more cautious approach helps minimise brain damage.
This rapid diagnosis means patients gain faster access to vital clinical trials, Smith highlighted. Dr Simon Paine, a consultant neuropathologist, emphasized the test’s clarity compared to microscopic examination. “I’m crystal ball gazing with a microscope,” he explained, “but the nanopore offers comprehensive molecular classification.”
The NHS is piloting this game-changing technology in specialist centres nationwide. Initially, five sites in Nottingham, Birmingham, London, and Newcastle are involved. The pilot will later expand to Bristol, Oxford, Leeds, and Manchester. More than 12,000 people receive a primary brain tumour diagnosis each year in the UK. Tragically, it remains the leading cancer killer for children and adults under 40.
Professor Frankie Swords, NHS medical director, emphasized the urgency. “For people with suspected brain tumours, a swift diagnosis feels like a race against time,” she explained. Waiting weeks for answers can cause immense distress. “This remarkable rapid brain tumour test has the potential to completely transform brain tumour diagnosis.” Results could reach patients in days, not weeks.
Professor Dame Sue Hill, chief scientific officer for England and senior responsible officer for genomics in the NHS, echoed this sentiment. She called it a “world-leading development for NHS genomics.” This test provides surgeons with vital information even before an operation concludes. The ultimate goal is to integrate this rapid testing into routine NHS care. This will ensure all patients benefit from faster, more precise diagnoses.
